Skip to content

Human molecular imaging aging and SuperAging cohort

Human molecular imaging aging and SuperAging cohort - SFB1436-Z03

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032449
Enrollment
400
Registered
2025-05-07
Start date
2022-01-11
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G30

Interventions

Group 1: In central project 3 (“Z03”), a cohort of cognitively healthy older adults is being established and deeply phenotyped. A subset of this cohort undergoes Tau-PET imaging using the tracer 18F-P

Sponsors

Otto-von-Guericke-Universität Magdeburg Medizinische Fakultät
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: Written informed consent - Preserved legal capacity of the subjects at the respective time of the examination - MRI suitability (not required if age >79) - For PET: PET suitability

Exclusion criteria

Exclusion criteria: 1. contraindications to MRI examinations: Pacemaker or defibrillator systems, tattoos, cochlear implants, insulin pumps, cerebral and ocular vascular clips or metal splinters, and marked claustrophobia, implants not suitable for MRI. 2. dementia syndromes 3. current severe neurological disease of the central nervous system (e.g. Parkinson's syndrome, motor neuron disease, temporal lobe epilepsy, multiple sclerosis) 4. current major depressive disorder and/or major neuropsychological disorder (schizophrenia, bipolar disorder) 5. current addiction (e.g. alcohol, psychological pharmaceuticals, cocaine, heroin) 6. serious internal diseases (e.g. diabetes mellitus) 7. Derailed vascular risk factors 8. advanced renal and cardiac insufficiency 9. severe visual or hearing impairment (uncorrected) 10. large tattoos 11. piercings 12. fear of confined spaces (claustrophobia) 13 contraindication for PET in young female participants: pregnancy

Design outcomes

Primary

MeasureTime frame
Multimodal characterization of the cohort by cognitive testing, MRI, blood markers

Secondary

MeasureTime frame
- Tau PET (part of the cohort) o Correlations between tau pathology and memory performance in the overall cohort o Correlations between tau pathology and brain structure/function in the overall cohort - Moderation analyses to test the hypothesis of "reserve/resilience", i.e. whether more neuronal resources (brain structure/function) lead to better cognition with the same degree of pathology. - Characterization of the change in the investigated parameters after 2 years o Regression model in total cohort, in which change in memory function after 2 years is predicted by baseline tau in the medial temporal lobe. o Characterization of regional tau PET accumulation after 2 years in the tau PET scan.

Countries

Germany

Contacts

Public ContactEmrah Düzel

Institut für kognitive Neurologie und Demenzforschung

emrah.duezel@med.ovgu.de0049-391-6725051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Sep 18, 2026